1: Home (ALT-H)
2: HMA Joint (ALT-M)
3: Human Medicines (ALT-U)
- 3.1: Heads of Agencies (ALT-E)
- 3.2: CMD(h) (ALT-C)
- 3.3: MRI Product Index (ALT-R)
- 3.4: Directory (ALT-I)
4: Veterinary Medicines (ALT-V)

You are here: Human Medicines > CMD(h) > Product Information > Core SPC/PL

3.2.1: About CMD(h) (ALT-O)
3.2.2: Statistics (ALT-S)
3.2.3: Press Releases (ALT-P)
3.2.4: Procedural Guidance (ALT-L)
3.2.5: CMD(h)-Referrals
3.2.6: Product Information (ALT-T)
- 3.2.6.1: PhVWP Recommendations (ALT-W)
- 3.2.6.2: CMD(h) Recommendations (ALT-N)
- 3.2.6.3: Harmonisation of SPCs - Article 30 Referrals (ALT-3)
- 3.2.6.4: Core SPC/PL
3.2.7: Advice from CMD(h)
3.2.8: Templates
3.2.9: CMD subgroups / working groups (ALT-G)
3.2.10: Paediatric Regulation
3.2.11: Questions & Answers (ALT-Q)
3.2.12: Contact Form
3.2.13: Contact Points
3.2.14: What's new history (ALT-Y)

Trivalent Influenza Vaccines

Core Summary of Product Characteristics (Latest revision: September 2009)
Clean version Click here
Track changes Click here

Core Package Leaflet (Latest revision: September 2009)
Clean version Click here
Track changes Click here

Core SPCs

(see also Post referral Phase)

In order to view some of the documents on this website you need Acrobat Reader
(click here to download)

Fludeoxyglucose (18FDG) - Core SPC (March 2005)
Click here

Hormone Replacement Therapy - Core SPC (December 2009)
Click here

Hormone Replacement Therapy - MRFG-PhVWP agreed updated core SPC (October 2002)
Click here

Hormone Replacement Therapy - SPC wording for medicinal products used in HRT with regard to increased risk of venous thromboembolism as agreed by the PhVWP (September 2001)
Click here

Hormone Replacement Therapy - SPC wording for medicinal products used in HRT with regard to increased risk of breast cancer as agreed by the PhVWP (July 2001)
Click here